From 1 November 2023, the shingles vaccine Shingrix® has replaced Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It is available for eligible people most at risk of complications from shingles.
A 2-dose course of Shingrix® is available for free for anyone who is:
- 65 years and older (non-Indigenous)
- A First Nations person aged 50 years and over
- Immunocompromised people aged 18 years and older with medical conditions including:
- haemopoietic stem cell transplant
- solid organ transplant
- haematological malignancy
- advanced or untreated HIV
Shingrix® is a 2-dose course with an interval of 2-6 months for immunocompetent people and an interval of 1-2 months for people who are immunocompromised. Unlike Zostavax®, Shingrix® does not contain any live virus so it can be given to people aged 18 years and over who are immunocompromised.
Shingrix® information is already listed on our HealthPathway for Immunisation in Adults.
For further information, visit the National Immunisation Program website.
For providers, please find some more information around the initial limited availability of Shingrix®, and some advice around how to prioritise the rollout.